ERBB2 and breast carcinoma: The MONARCH study series enrolled patients with hormone receptor positive, ErbB2-negative advanced breast cancer and led to FDA approval of abemaciclib as initial endocrine-based therapy in combination with an aromatase inhibitor [75].